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ABSTRACT  
Objective: Synthesis, anticancer and antituberculosis studies for 1-(4-Chlorophenyl) cyclopropyl] (piperazin-1-yl) methanone derivates 3a-j 
Methods: A series of new [1-(4-Chlorophenyl) cyclopropyl] (piperazin-1-yl) methanone derivates were synthesized using reductive amination 
method in presence of sodium triacetoxyborohydride to yield piperzine derivatives 3a-j. The structures of all newly synthesized compounds have 
been characterised by elemental analysis and spectral studies.  
Results: Five selected compounds have been screened for invitro anticancer activity against human breast cancer cell line MDA-MB-435 at 10, 20, 
40 and 80 µG/mL concentration using sulforhodamine B assay method. and Two compounds 3a and 3c have shown in vitro anticancer activity. 
Five selected compounds have been screened for anti-tuberculosis activity using Middlebrook 7H-9 broth and standard strain of M. tb h37Rv. Three 
compounds 3a, 3b and 3c have shown significant antituberculosis  
Conclusion: Synthesis of [1-(4-Chlorophenyl) cyclopropyl] (piperazin-1-yl) methanone derivates 3a-j simple and convenient method. Some of the 
tested compounds have exhibited significant antituberculosis and anticancer activity. Compound 3c showed both antituberculosis and anticancer 
activity. 
Keywords: Piperazine, Aldehydes, Cyclopropane, Antituberculosis, Anticancer. 
 
INTRODUCTION 
Disubstituted piperazines exhibit wide range of biological properties 
as reported in the literature. In the last decade, a number of 
piperazine derivatives have been synthesized and evaluated for their 
cytotoxic activity [1-6]. Additional clinical drug development studies 
of the piperazine compounds in small-animal models by the US 
National Cancer Institute (NCI) demonstrated that these targets had 
the ability to suppress experimental tumours.  
As a result of the study for the lead compounds, It has been reported 
that inhibitory action was observed against colon, prostate, breast, 
lung and immune cell tumours in many indole carrying small anti 
cancer molecules [7]. In addition, piperazines have been found to 
posses several biological activities [8-11] including antituberculosis 
activity [12]. The polarity of nitrogen atoms of piperazine ring 
enhances favourable interaction with bio macromolecules and thus 
confers the biological activity [13-14]. Thus, based on these 
observations in the literature, the present study was initiated with 
aim of identifying the structural requirements of piperazines in 
terms of anticancer and antitubercular activity. 
MATERIALS AND METHODS 
Chemistry 
All the chemicals and solvents used in this work were of analytical 
reagent grade (anhydrous) and purchased from Sigma-Aldrich. All 
the IR spectra were recorded on Bruker alpha FTIR 
spectrophotometer, 1H NMR spectra were measured on Bruker AV 
400MHZ using CDCl3 and DMSO as solvent. Chemical shifts are 
expressed in δ ppm.  
Elemental Analysis was performed on an Elementar Vario EL 
elemental analyzer. Satisfactory C, H, N analyses were obtained for 
all the compounds. All the reactions were followed and checked by 
TLC (silica coated on alumina) using ethylacetate-pet ether (3:7) and 
further purification was done by column chromatography using 60-
120 mesh silica gel. 
Synthesis of 1-(4-Chlorophenyl) cyclopropyl] (piperazin-1-yl) 
methanone derivatives (3a-j) 
1-(4-Chlorophenyl) cyclopropyl] (piperazin-1-yl) methanone (1.0 
eq) was dissolved in dry THF (10 mL). The solution was stirred for 
10 min at ambient temperature. Then added substituted aldehydes 
(1.1 eq), followed by sodium triacetoxyborohydride (1.4 eq) and 
glacial acetic acid (1.5 eq). The reaction mixture was heated at 65-
700C for 12-14 hr. The completion of reaction was monitored by 
TLC. The reaction mixture was diluted with ethyl acetate, the organic 
layer was washed with 10% sodium bicarbonate, followed by water, 
and brine solution and dried over anhydrous sodium sulphate. The 
organic layer was evaporated under reduced pressure and the crude 
reaction mixture was purified by column chromatography using 60-
120 mesh silica gel and 20% ethyl acetate in hexane. The series of 
reactions carried out have been depicted in scheme 1. 
 
Scheme 1: Synthesis of piperazine methanone derivatives 3a-j. 
 
1. t-Butyl 4-(1-(4-Chlorophenyl) cyclopropanecarbonyl) 
piperazine-1-carboxylate (1) 
1-(4-Chlorophenyl) cyclopropanecarboxylic acid (2.00 g, 0.0102 
mol) was dissolved in dry tetrahydrofuran (20 mL). The solution 
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was stirred for 10 min at ambient temperature. 1-Ethyl-3-(3-
dimethyllaminopropyl)carbodiimide hydrochloride (2.15 g, 0.01122 
mol) was added, followed by 1-hydroxybenzotriazole (1.718 g, 
0.01122 mol) and N,N-diisopropylethylamine (3.955 g,0.0305 mol). 
The reaction mixture was stirred for 20 min at ambient temperature, 
and then it was cooled to 0°C. Boc-piperazine (tert-butyl piperazine-
1-carboxylate) (1.894 g, 0.0102 mol) was added portion-wise to the 
reaction mixture and stirring was continued for 6 h at ambient 
temperature.  
The completion of the reaction was monitored by TLC. The reaction 
mixture was diluted with ethyl acetate (25 mL) and washed with 
sodium bicarbonate (10%, 25 mL) followed by water (15 mL) and 
brine (15 mL) and dried over sodium sulphate (5.0 g) and evaporate 
under reduced pressure. The crude reaction mixture was purified by 
column chromatography using silica gel and 10% ethyl acetate in 
hexane to get 3.4 g of t-butyl 4-(1-(4-chlorophenyl) 
cyclopropanecarbonyl) piperazine-1-carboxylate (1).  
LC-MS (ESI, Positive): m/z: [M+H]+: 365.2; 1H NMR: (400 MHz, 
DMSO-d6): δ 7.40 (d, J = 2.0 Hz, 2H), 7.17 (d, J = 3.0 Hz, 2H), 3.63 (m, 
2H), 2.96 (m, 2H), 1.37 (q, 2H), 1.18 (q, 2H); 1.2 (s, 9H), IR (KBr) ν 
(cm-1):1646 (C=O); Elemental analysis: Calculated (%) for 
C14H17ClN2O:C 62.54, H 6.91, N 7.68; Found: C 62.55, H 6.94, N 7.62 
2. [1-(4-Chlorophenyl)cyclopropyl](piperazin-1-yl)methanone (2) 
Compound 1 (3.4 g, 0.00934 mol) was dissolved in dry 
Dichloromethane (20 mL) and the reaction mixture was cooled to o 
to 50C. Trifluoroacetic acid (3.19 g, 0.028 mol,3.0 eq) was added 
slowly to the cooled reaction mixture and stirred for 6 h at ambient 
temperature. The completion of the reaction was monitoring by TLC. 
 The reaction mixture was evaporated under reduced pressure and it 
was dissolved in Dichloromethane (30 mL). Organic layer was 
washed with water (15 mL), brine (15 mL) and dried over sodium 
sulphate (6 g).  
The crude reaction mixture obtained was purified by column 
chromatography using silica gel and 3% methanol in 
Dichloromethane to get 1.8 g of purified [1-(4-chlorophenyl) 
cyclopropyl] (piperazin-1-yl)methanone (2). LC-MS (ESI, Positive): 
m/z: [M+H]+: 265.2; 1H NMR: (400 MHz, DMSO-d6): δ 9.32 (s, 1H, 
NH), 7.40 (d, J = 2.0 Hz, 2H), 7.17 (d, J = 3.0 Hz, 2H), 3.63 (m, 2H), 
2.96 (m, 2H), 1.37 (q, 2H), 1.18 (q, 2H); 13C NMR (100 MHz, DMSO-
d6): 169.9, 139.9, 131.3, 129.1 127.5 42.6, 28.89 15.7 (2C); IR (KBr) ν 
(cm-1): 2970 (N-H), 1646 (C=O); IR (KBr) ν (cm-1): 1646 (C=O); 
Elemental analysis: Calculated for C14H17ClN2O:C 63.51,H 6.47 N, 
10.58; Found: C, 63.53 H 6.46, N 10.57. 
3. General procedure preparation of methanone derivates (3a-j). 
Compound 2 (0.5 g, 0.00188 mol) was dissolved in dry THF solvent 
(10mL). The solution was stirred for 10 min at ambient temperature. 
Substituted aldehydes(0.0020 mol) was added, followed by sodium 
triacetoxyborohydride (0.557g,0.002632 mol) and Glacial acetic acid 
(0.169 g,0.00282 mol). 
The reaction mixture was heated at 65-700C for 12-14 hr. The 
completion of reaction was monitored by TLC. The reaction mixture 
was diluted with ethyl acetate, the organic layer was washed with 
10% sodium bicarbonate solution followed by water, brine and 
dried over anhydrous sodium sulphate. The organic layer was 
evaporated under reduced pressure and the crude reaction mixture 
was purified by column chromatography using 60-120 mesh silica 
gel and 3% methanol in dichloromethane. 
3.1. 4-((1H-indol-3-yl) methyl) piperazin-1-yl)(1-(4Chlorophenyl) 
cyclopropyl)methanone (3a) 
LC-MS (ESI, Positive): m/z: [M+H]+: 394.9; 1H NMR (400 MHz, 
DMSO-d6): δ 10.92 (bs, 1H, NH), 7.59-7.58 (d, J = 6.4 Hz, 1H), 7.35-
7.33 (m, 3H), 7.19-7.13(m, 3H),7.08-6.96(m, 1H) 3.60-3.33 (m, 6H), 
2.31-1.91(m, 4H), 1.27-1.25 (m, 2H), 1.16-1.14 (m, 2H), 1.18 (q, J = 
5.0 Hz, 2H); IR (KBr) ν(cm-1): 3266 (N-H),817 (C-Cl); Elemental 
analysis: Calculated (%) for C23H24ClN3O:C 70.13, H 6.14, N 10.64; 
Found: C 70.15, H 6.12, N 10.50. 
3.2. 1-(4-Chlorophenyl) cyclopropyl) (4-(pyridin-3-ylmethyl)  
piperazin-1-yl)methanone (3b) 
LC-MS (ESI, Positive): m/z: [M+H]+: 356.8; 1H NMR (400 MHz, 
DMSO-d6): δ 8.50-8.48 (dd, J = 4.4 Hz, 2H), 7.38-7.35 (m, 2H), 7.30-
7.28 (d, J = 6.0 Hz, 2H), 7.18-7.15(m, 2H) 3.47 (s, 2H), 3.45-3.38 (m, 
4H), 3.34-2.30 (m, 4H)1.31-1.28 (m, 2H), 1.18-1.15 (m, 2H). IR (KBr) 
ν(cm-1): 1718 (C=O), 760 (C-Cl) Elemental analysis: Calculated (%) 
for C20H22ClN3O: C 67.50, H 6.23, N 11.81; Found: C 67.52, H 6.22, N 
11.78. 
3.3. 1-(4-Chlorophenyl) cyclopropyl) (4-(quinolin-6-ylmethyl) 
piperazin-1-yl)methanone (3c) 
LC-MS (ESI, Positive): m/z: [M+H]+: 406.9; 1H NMR (400 MHz, 
DMSO-d6): δ 8.95-8.93(m,1H) 8.86-8.85 (m, 1H), 8.49-8.47 (m,1H) 
7.77-7.4 (m, 2H), 7.35-7.30 (m, 2H), 7.29-7.27(m, 1H) 7.21-7.15(m, 
2H), 3.62 (s, 2H), 3.45-3.38 (m, 4H), 3.34-2.30(m, 4H)1.30-1.27 (m, 
2H), 1.17-1.14 (m, 2H). Elemental analysis: Calculated (%) for 
C24H24ClN3O: C 71.01, H 5.96, N 10.35; Found: C 71.10, H 6.01,N 
10.41. 
3.4. 4-((1H-imidazol-2-yl) methyl) piperazin-1-yl) (1-(4-
chlorophenyl) cyclopropyl) methanone (3d) 
LC-MS (ESI, Positive): m/z: [M+H]+: 345.8; 1H NMR (400 MHz, 
DMSO-d6): δ 13.5 (bs, 1H), 7.55 (s,1H),7.38-7.31(m, 2H) 7.19-7.15 
(m, 2H), 6.92(s, 1H)3.46(s, 2H)3.45-3.38(m, 4H) 2.40-2.24 (m, 4H), 
1.31-1.28 (m, 2H), 1.18-1.15 (m, 2H). IR (KBr) ν(cm-1): 1699 
(C=O),773 (C-Cl); 3338 (N-H); Elemental analysis: Calculated (%) for 
C18H21ClN4O: C 62.69, H 6.14, N 16.25; Found: C 62.71, H 6.16, N 
16.31. 
3.5. 1-(4-Chlorophenyl) cyclopropyl) (4- ((5-nitrothiazol-2-yl) 
methyl) piperazin-1-yl)methanone (3e) 
LC-MS (ESI, Positive): m/z: [M+H]+: 406.1; 1H NMR (400 MHz, 
DMSO-d6): δ 8.01-8.00 (d, J = 4.4 Hz, 1H), 7.38-7.35 (d, J = 8.8 Hz, 
2H), 7.18-7.16 (d, J =8.8 Hz, 2H), 7.09-7.08 (d, J =4.0 Hz, 1H),3.74 (s, 
2H), 3.45-3.38(m, 4H) 2.40-2.24 (m, 4H), 1.32-1.29 (m, 2H), 1.18-
1.15 (m, 2H). 13C NMR (400 MHz,CDCl3): δ 169.30, 153.65, 147.72, 
139.97, 130.75, 130.15, 128.64, 127.11,125.68, 56.08, 51.99, 28.68, 
15.8, Elemental analysis: Calculated (%) for C19H20ClN3O3S: C 53.13, 
H 4.71, N 13.77; Found: C 53.18, H 4.70, N 13.73. 
3.6. 1-(4-Chlorophenyl)cyclopropyl) (4-((6-methylpyridin-2-yl) 
methyl) piperazin-1-yl)methanone (3f) 
LC-MS (ESI, Positive): m/z: [M+H]+: 370.8; 1H NMR (400 MHz, 
DMSO-d6): δ 7.63-7.59 (m, 1H), 7.37-7.34 (d, J = 8.4 Hz, 2H), 7.19-
7.14 (m, 3H), 7.10-7.08 (m, 1H), 3.74 (s, 2H), 3.49-3.40(m, 4H), 2.36 
(s, 3H) 2.33-2.19 (m, 4H), 1.30-1.27 (m, 2H), 1.17-1.14 (m, 2H). 13C 
NMR (400 MHz,DMSO-d6): δ 169.65, 157.52, 140.44, 137.18, 131.12, 
129.03, 127.51, 212.84, 120.12, 63.94, 52.70, 29.10, 24.43, 15.75.IR 
(KBr) ν(cm-1): 1698 (C=O),779 (C-Cl); Elemental analysis: Calculated 
(%) for C21H24ClN3O: C 68.19, H 6.54, N 11.36; Found: C, 68.21, H 
6.50, N 11.31. 
3.7. 1-(4-Chlorophenyl)cyclopropyl)(4-((1-methyl-1H-pyrrol-2-yl) 
methyl) piperazin-1-yl)methanone (3g) 
LC-MS (ESI, Positive): m/z: [M+H]+: 358.8; 1H NMR (400 MHz, 
DMSO-d6): δ 7.38-7.35 (m, 2H), 7.20-7.14 (m, 2H), 6.64-6.63 (m, 1H), 
5.84-5.83 (m, 2H), 3.54 (s, 2H), 3.46-3.39 (m, 4H), 3.34 (s, 3H) 2.23-
2.11 (m, 4H), 1.29-1.26 (m, 2H), 1.18-1.14 (m, 2H). IR (KBr) ν(cm-1): 
1714 (C=O),779 (C-Cl); Elemental analysis: Calculated (%) for 
C20H24ClN3O: C 67.12, H 6.76, N 11.74; Found: C 67.11, H 6.72, N 
11.71. 
3.8. 4-(4-Phenoxybenzyl) piperazin-1-yl)(1-(4-Chlorophenyl) 
cyclopropyl)methanone (3h) 
LC-MS (ESI, Positive): m/z: [M+H]+: 447.1; 1H NMR (400 MHz, 
DMSO-d6): δ 8.50-8.48 (dd, J = 4.4 Hz,1.4Hz 2H), 7.38-7.35 (m, 2H), 
7.30-7.28 (d, J = 6.0 Hz, 6H), 7.18-7.15(m, 5H), 7.00-6.95 (2m, H) 
3.49 (s, 2H), 3.47-3.40 (m, 4H), 3.36-2.32 (m, 4H)1.32-1.29 (m, 2H), 
1.19-1.16 (m, 2H).Elemental analysis: Calculated (%) for 
C27H27ClN2O2: C 72.55, H 6.09, N 6.27; Found: C 72.61, H 6.29, N 6.12. 
 
 
Table 1: Synthesis of piperazine methanone derivatives 3a-j 









































































































































































3.9. 1-(4-Chlorophenyl) cyclopropyl) (4-((4,5-dimethylfuran-2-yl) 
methyl)piperazin-1-yl)methanone (3i): 
 LC-MS (ESI, Positive): m/z: [M+H]+: 373.8; 1H NMR (400 MHz, 
DMSO-d6): δ 7.39-7.34 (m, 2H), 7.19-7.14 (m, 2H), 5.59 (s, 1H), 3.6 (s, 
2H), 3.46-3.39 (m, 4H), 2.23-2.11 (m, 4H), 2.10 (s, 3H)1.92 (s, 3H), 
1.19-1.15 (m, 2H).  
13C NMR (400 MHz, DMSO-d6): δ 169.62, 148.62, 146.59, 140.44, 
131.13, 129.01, 127.54, 114.39, 112.51, 54.30, 52.06, 29.10, 15.68, IR 
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(KBr) ν(cm-1): 1710 (C=O); Elemental analysis: Calculated (%) for 
C21H25ClN2O2: C 67.64, H 6.76, N 7.51; Found: C 67.68, H 6.72 N 7.52. 
3.10. 1-(4-Chlorophenyl) cyclopropyl) (4-((1,3-dimethyl-1H-
pyrazol-4 yl) methyl)piperazin-1-yl)methanone (3j) 
LC-MS (ESI, Positive): m/z: [M+H]+: 373.8; 1H NMR (400 MHz, 
DMSO-d6): δ = 8.31 (s, 1H ),7.39-7.35 (m,2H ) 7.20-7.14 (m, 2H), 3.69 
(s, 2H), 3.46-3.39 (m, 4H),3.18 (s, 3H), 2.35 (s,3H), 2.23-2.11 (m, 4H), 
1.19-1.15 (m, 2H).  
IR (KBr) ν(cm-1):779 (C-Cl) Elemental analysis: Calculated (%) for 
C20H25ClN4O: C 64.42, H 6.76, N 15.02; Found: C 64.48, H 6.78, N 
15.08. 
Anticancer activity 
Five selected compounds have been screened for invitro anticancer 
activity against human breast cancer cell line MDA-MB-435 at 10, 20, 
40 and 80 µG/mL concentration using sulforhodamine B assay 
method. The activity was carried out by Advanced Centre for 
Treatment, Research and Education in Cancer (ACTREC) Mumbai. 
Adriamycin (Doxorubicin) was used as positive control drug for 
comparing anticancer efficiency and DMSO as vehicle. Two compounds 
have been found to show dose dependent activity against breast cancer. 
The parameters GI50, TGI and LC50 have been reported. The results 
have been incorporated in Table 1 and diagram. Compounds 3a and 3c 
were found to show dose dependent activity. 
 
Table 2: Anticancer activity against Human Brest Cancer Cell Line MDA-MD-435 
Drug Concentration (µg/ml) 
 Experiment 1 Experiment 2 Experiment 3 aAverage Values 
Comp 10 20 40 80 10 20 40 80 10 20 40 80 10 20 40 80 
3a 45.3 5.4 -4.4 -90.8 60.7 9.1 -35.6 -63.7 60.5 13.9 -45.7 -81.8 55.5 9.5 -28.6 -78.8 
3b 92.7 65.6 46.7 25.8 108.3 81.6 60.7 30.1 87.2 94.6 59.3 11.4 96.1 80.6 55.6 22.4 
3c 15.8 -28.1 -69.8 -91.6 60.9 39.6 7.5 -69.8 59.2 27.9 -14.3 -87.6 43.2 13.1 -25.5 -83.0 
3d 79.1 99.2 71.9 38.2 82.1 95.0 86.4 35.8 90.9 99.9 84.1 23.0 84.0 98.0 80.8 32.4 
3e 86.8 83.4 55.0 4.6 90.8 84.6 61.8 11.4 86.2 84.7 42.2 -18.7 87.9 84.2 53.0 -0.9 
ADR -34.2 -50.3 -55.1 -25.2 7.8 10.5 5.4 0.3 -36.9 -64.9 -43.0 -42.3 -21.1 -34.7 -30.9 -22.4 
a Average values of tested compounds 
 
 
Fig. 1: Graphical representation of anticancer activity 
 
Table 3: Parameter study table (LC50, TGI, and GI50) 
Compound LC50 TGI GI50 
3a 60.2 36.5 12.7 
3b >80 >80 51.7 
3c 59.4 35.5 11.7 
3d >80 >80 66.9 
3e >80 >80 42.6 
ADR >80 29 <10 
 
Anti tuberculosis activity 
Procedure for Anti Tb 
The procedure we have followed for anti-Tb activity mainly involves 
the use of Middlebrook 7H-9 broth and standard strain of M. tb 
h37Rv. The basal medium was prepared according to manufacture's 
instructions (Hi-Media) and sterilized by autoclaving. 4.5 ml of broth 
was poured into each one of the sterile bottles. To this, 0.5ml of ADC 
supplement was added. This supplement contains catalase, dextrose 
and bovine serum albumin fraction v. Then a stock solution of the 
compound was prepared (10mg / ml). From this appropriate 
amount of solution was transferred to media bottles to achieve final 
concentrations of 25, 50, 100µg/ml. Finally, 10 ul suspension of M. tb 
strain (100000 organisms / ml, adjusted by McFarland's turbidity 
standard) was transferred to each of the tubes and incubated at 
370c. Along with this, one growth control without compound and 
drug controls was also set up. The bottles were inspected for growth 
twice a week for a period of three weeks. The appearance of 
turbidity was considered as growth and indicates resistance to the 
compound. The growth was confirmed by making a smear from each 
bottle and performing a ZN stain. Antibiotic standards used include 
streptomycin 7.5µg/ml and Pyrazinamide 7.5µg/ml. 
 
Table 4: Anti tuberculosis studies of synthesised compounds 
S. No. Compound 5 µg/ml 10 µg/ml 25 µg/ml 
1 3a S S S 
2 3b S S S 
3 3c S S S 
4 3d R R R 
5 3e R R R 
 
RESULTS AND DISCUSSION 
All the synthesized compounds have been purified by column 
chromatography and recrystalized with ethyl acetate. The structures 
have been confirmed by elemental analysis and spectroscopic 
techniques like IR, 1H-NMR, LC-MS. Some of the selected compounds 
have been tested for invitro anticancer and antituberculosis activity. 
Two compounds have been found to show dose dependent activity 
against cervical cancer. The parameters GI50, TGI and LC50 have 
been reported. The results have been incorporated in Table 1 and 
diagram. Compounds 3a and 3c were found to show dose dependent 
activity Out of these tested compounds 3a, 3b and 3c have been 
found active against tuberculosis. In the above table 3, R indicates 
resistivity and S indicates sensitivity of the tested compounds 
against the standard. 
CONCLUSION 
The research work is focused on the efficient synthesis of 
cyclopropyl piperazine derivatives. The reactions performed are 
eco-friendly. In addition, some of the tested compounds have 
exhibited significant antituberculosis and anticancer activity. The 
publication of these facts would be of significant use for the scientific 
community. Some selected cyclopropyl piperazine derivatives have 
been tested for antituberculosis and invitro anticancer activity. 
Three compounds 3a, 3b and 3c have shown significant 
antituberculosis and two compounds 3a and 3c have shown in vitro 
anticancer activity. Recommended compounds have been under 
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screen for invivo anticancer activity. Compound 3c showed both 
antituberculosis and anticancer activity. 
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